RespireRx Pharmaceuticals Inc (fka RSPI)

[bladerunner1717]

"That may be why the FDA apparently didn't notice the cellular changes originally, before the Phase 2as - no one had seen anything like it before, so they weren't looking for it. What we really need to worry about now, along with everything else, is what a thorough tox reexamination of Org-24448 might reveal"

My thoughts exactly, gfp.

And where to look and what to look for is the kind of "trade secret" that Stoll has no intention of revealing to potential competitors. I can appreciate that.

What also is worrisome is that the ADHD indication will fall under the jurisdiction of the psychiatric division in the CNS larger division. The new guy in the psychiatric division will surely be ultra-conservative in these matters, and that could spell further trouble for CX717 in ADHD down the line.



Bladerunner